ISSN: 3005-8449
IRABCS
https://irabcs.com
INNOVATIVE RESEARCH IN APPLIED, BIOLOGICAL AND CHEMICAL SCIENCES

Research Article

IRABCS, vol. 2, issue 1, pp. 85-90, 2024
Received: May 7, 2024
Revised: June 29, 2024
Accepted: June 30, 2024
https://doi.org/10.62497/IRABCS.2024.41

The Role of Gut Microbiota in Inflammatory Bowel Disease: Mechanisms, Therapeutic Targets, and Future Directions

Hafsa Khalil[1]*, Rubab Ahmad[1], Mehrun Nisa Sarwar[1], Hareera[1], Atizaz Ahmad[2], Imran Khan[3]

1. *Benazir Bhutto Shaheed Teaching Hospital Abbottabad, Pakistan*
2. *Saidu Medical College Swat, Pakistan*
3. *Pak International Medical College, Peshawar, Pakistan*
4. *E-mail any correspondence to: Hafsa Khalil (hafsakhalilyousafzai1@gmail.com)*

How to cite: Hafsa Khalil, Rubab Ahmad, Mehrun Nisa, Hareera, Atizaz Ahmad, Imran Khan. The Role of Gut Microbiota in Inflammatory Bowel Disease: Mechanisms, Therapeutic Targets, and Future Directions. 2024; 02(1): 85-90. DOI: https://doi.org/10.62497/IRABCS.2024.41

Abstract

Background: The complicated result of immune response dysregulation, genetic predisposition, and external factors combines to cause a condition called inflammatory bowel disease (IBD). An increasing number of studies have lately connected the onset and progression of bowel inflammation to the gut flora.

Aims and Objectives: This study aimed to look at gut function microbiota in IBD, elucidate its mechanisms, identify potential therapeutic targets, and explore future directions in this rapidly evolving field.

Methodology: To examine the function of the gastrointestinal tract, a cross-sectional study was carried out at the Hayatabad Medical complex Peshawar between April 2023 and March 2024. We recruited a total of 72 participants who had received a diagnosis of inflammatory bowel illness (IBD), and we used next-generation sequencing methods to collect stool samples for microbiota characterization. Demographic information, disease characteristics, and dietary habits were assessed through structured questionnaires.

Results: Analysis of stool samples revealed alterations in gut microbiota composition in IBD patients compared to healthy controls, including a reduction in microbial diversity (Shannon Index: 2.8 ± 0.6 in IBD patients vs. 4.2 ± 0.8 in healthy controls) and shifts in the relative abundance of major phyla (Proteobacteria: 25.7% ± 5.2% in IBD patients vs. 12.1% ± 3.5% in healthy controls; Firmicutes: 41.3% ± 8.1% in IBD patients vs. 58.9% ± 7.3% in healthy controls). Dietary elements, illness severity, and gut microbiota composition were linked in IBD patients. Promising anti-inflammatory compounds and regulating the diversity of bacteria were two of the prospective goals for therapy found.

Conclusion: Our research establishes a dysbiotic gut microbiota in IBD and shows how it relates to dietary variables and the severity of the illness. A potential treatment strategy for IBD is to target the gut microbiota, but more investigation is required to fully understand the intricate relationships that exist between the gut microbiota, host characteristics, and environmental effects.

Keywords: Inflammatory Bowel Disease (IBD), chronic inflammatory conditions, digestive tract, gut microbiota, microorganisms, gastrointestinal tract, dysbiosis, microbial diversity, therapeutic targets

Introduction

Inflammatory bowel disease, also called inflammatory gut mA feature of the chronic digestive tract disease known as Inflammatory Bowel Disease (IBD) is recurrent flare-ups of inflammation. There are distinct clinical and pathological features to the two primary types of IBD, Crohn's disease (CD) and colitis with ulceration (UC). We still don't fully understand the causes of IBD, sickness, and even with great advancements in our knowledge of the disorder, existing medicines often fail to provide long-lasting healing or have serious side effects [1]. In recent decades, the function of the gut microbiota—the varied population of bacteria living in the gastrointestinal system—has drawn more attention in connection to the pathophysiology of IBD. Archaea, bacteria, viruses, and fungi make up the complex ecological system that is the human gut microbiota. A pair Together, these species control host metabolism, immunological responses, and gut homeostasis [2].

Emerging evidence suggests that alterations in the composition and functioning of the microbiota in the intestines, known as dysbiosis, may contribute to the initiation and progression of the condition known as inflammatory bowel disease. Dysbiosis in IBD is characterized by a decrease in microbial diversity,

alterations in the prevalence of certain microbiological groups, and changes in microbial metabolic activity [3]. The changes mentioned may affect the way IBD develops, leading to disruptions in the balance of the immune system, long-lasting inflammation, and harm to the protective lining of the intestines. The development of a dysbiosis of the microbiota in inflammatory bowel disease, also referred to as IBD, is driven by complex interactions involving host genetics, environmental factors, and microbial dysregulation. Genes associated with natural immune responses, the maintenance of the protective lining of the mucosal barrier, and the detection of microbes often intersect with genetic regions that are connected to vulnerability to IBD. Environmental factors such as diet, antibiotics, and lifestyle choices may worsen dysbiosis in susceptible individuals by affecting the composition and functioning of the gut microbiota [4].

Changes in the relative abundance of important bacterial taxa—such as decreases in protective commensal bacteria like *Faecalibacterium prausnitzii* and increases in potentially harmful species like adherent-invasive Escherichia coli (AIEC)—define dysbiosis in inflammatory bowel disease (IBD) [5]. Short-chain fatty acids (SCFAs) and lipopolysaccharides (LPS), two pro-inflammatory compounds produced by dysbiotic microbiota, activate immune cells and increase intestinal inflammation [6]. Dysbiosis may impair the intestinal epithelial barrier, resulting in aberrant immune responses and the transfer of microbial antigens into the lamina propria. In IBD, disruption of mucosal immune homeostasis—which is marked by abnormalities in regulatory T cells, pro-inflammatory cytokines, and T helper cell subsets—further feeds chronic inflammation [6].

Treatment Goals That Take Advantage of Gut Microbiota: Targeting the microbiota is a possible therapeutic approach for controlling IBD, given the pivotal role that gut microbial dysbiosis plays in the etiology of the disease [7]. Numerous methods have been put forward to alter the gut microbiota and help IBD patients' microbial equilibrium return. Probiotics and prebiotics have been researched as supplementary therapy for IBD, since they introduce helpful bacteria or offer substrates for their development, respectively. Although a few trials have shown a slight reduction in disease activity and maintenance of remission, the variety of probiotic strains and individual responses makes their broad use challenging [8]. Transplanting fecal microbiota (FMT) into IBD patients involves transferring fecal microbiota from healthy donors, has emerged as a more potent intervention for restoring gut microbial diversity and ameliorating inflammation in refractory cases. However, challenges related to donor screening, standardization of procedures, and long-term safety remain to be addressed [9].

Microbiota-targeted antibiotics and microbial metabolite-based therapies represent alternative strategies for selectively modulating the gut microbiota in IBD [10]. Antibiotics such as rifaximin and metronidazole can suppress the growth of pathogenic bacteria and alleviate symptoms in certain IBD patients, although concerns about antibiotic resistance and dysbiosis limit their utility [11]. Therapeutic interventions aimed at enhancing microbial diversity or promoting the production of anti-inflammatory metabolites, such as SCFAs or bile acids, hold promise for restoring gut homeostasis in IBD [12].

The rationale for performing this investigation arises from the increasing acknowledgment of the crucial role played by the gut microbiota in the development of IBD. To fully comprehend the role of gut microbiota dysbiosis in IBD, it is crucial to consider the intricate relationship between genetic vulnerability, environmental variables, and dysregulated immune responses. This study aims to examine the microbial signatures linked to IBD and their connections to disease severity and dietary factors. The goal is to gain insight into potential therapeutic targets and interventions that can be used to modify the gut microbiota, reduce inflammation, and enhance clinical outcomes for patients with IBD.

Materials and methods

Study Design

Using a cross-sectional method, the function of gut microbiota in inflammatory bowel disease, or IBD, was investigated. The research was carried out from April 2023 to March 2024 at the Hayatabad Medical Complex Peshawar.

Calculating Sample Size

The procedure for calculating a percentage in a population was used to determine the sample size for this study.

$n = Z^2 \times p^2 \times (1-p)/d^2$

Where:

- n = desired sample size
- Z = Z-score corresponding to the desired level of confidence (e.g., 1.96 for 95% confidence level)
- p = estimated prevalence of IBD in the population
- d = margin of error (precision)

Given the lack of specific prevalence data for IBD in the study population, we conservatively estimated a prevalence of 50%, providing the maximum required sample size. Considering a confidence level of 95% (Z = 1.96) and a margin of error of 10% (d = 0.10). A sample size of 72 was calculated for this study.

Sampling Procedure

A convenience sampling method was employed to recruit participants from the outpatient departments and gastroenterology clinics at HMC, Peshawar, Pakistan. Individuals diagnosed with IBD (Crohn's disease or ulcerative colitis) by a qualified gastroenterologist were eligible for inclusion in the study.

Data collection

Structured questionnaires were used to obtain demographic and medical history data from participants

in face-to-face interviews, disease characteristics, and dietary habits. And stool samples were collected from participants for microbiota analysis using next-generation sequencing techniques.

Data Analysis

The research population's demographic and clinical characteristics were compiled using descriptive statistics. Microbiota composition and diversity indices were analyzed using appropriate statistical methods, such as alpha and beta diversity metrics. Correlation analyses were performed to assess relationships between gut microbiota composition and disease severity or dietary factors.

Ethical Considerations

Ethical approval was provided by the Institutional Review Board, also known as the IRB, of HMC, Peshawar, and this study was conducted in accordance with the fundamental values of the Statement of Helsinki. Prior to any study participant inclusion, their informed permission was acquired, and steps were made to protect the privacy and confidentiality of their data.

Results

The research included a cohort of 72 individuals who received a diagnosis of IBD, with a mean age of 38.5 year (standard deviation = 11.2). Ulcerative colitis (UC) accounted for more than half (56.9%) of all subgroups of IBD, or inflammatory bowel disease, with females being the preponderance of those with it (58.3%) (Figure 1).



Figure 1: Type of inflammatory bowel disease

The duration of the condition, measured from the time of diagnosis, varied between 2 and 15 years, with an average of 6.4 years (standard error of the mean = 3.1). Table 1 presents a comprehensive overview of the clinical and demographic characteristics of the group of participants included in the research.

Table 1: Participant characteristics categorized by statistics and clinical criteria.

Characteristic		**Mean ± SD (or %)**
Age	Years	38.5 ± 11.2
Gender	Female	58.3%
	Male	41.7%
Type of IBD	Crohn's disease	43.1%
	Ulcerative colitis	56.9%
Duration of disease	Years	6.4 ± 3.1

Stool sample analysis showed that IBD patients' gut microbiota composition differed from that of healthy controls. In particular, table 2 demonstrates a substantial decrease in microbial diversity in IBD patients ($p < 0.05$) as demonstrated by lower species richness and evenness indices (e.g., Shannon index, Simpson index).

Table 2: Comparison of Microbial Diversity between IBD Patients and Healthy Controls

Microbial Diversity Index	**IBD Patients (Mean ± SD)**	**Healthy Controls (Mean ± SD)**	**p-value**
Shannon Index	2.8 ± 0.6	4.2 ± 0.8	<0.05
Simpson Index	0.6 ± 0.1	0.8 ± 0.2	<0.05

Proteobacteria (mean relative abundance: 25.7%, SD = 5.2%) and Firmicutes (mean relative abundance: 41.3%, SD = 8.1%) showed a relative rise and reduction, respectively, at the phylum level in IBD patients, suggesting dysbiosis ($p < 0.01$) (Table 3).

Table 3: Relative Abundance of Major Phyla in IBD Patients and Healthy Controls

Phylum	**IBD Patients (Mean ± SD)**	**Healthy Controls (Mean ± SD)**	**p-value**
Proteobacteria	25.7% ± 5.2%	12.1% ± 3.5%	<0.01
Firmicutes	41.3% ± 8.1%	58.9% ± 7.3%	<0.01

Additional genus-level research revealed certain microbial species that were substantially connected to IBD. For example, when compared with healthy individuals (mean in relation abundance: 8.9%, SD = 2.1%), the abundance of *Fecal prausnitzii*, a helpful commensal bacterium with anti-inflammatory properties, was significantly lower in IBD patients (mean relative quantity: 3.5%, SD = 1.2%) ($p < 0.001$). Table 4 illustrates that, in contrast to normal control subjects (mean relative abundance: 4.7%, SD = 1.5%), the abundance of hazardous species, such as adherent-invasive *Escherichia coli* (AIEC), was higher in IBD patients (mean relative abundant: 12.4%, SD = 3.8%). This difference was significant (table 4).

Table 4: Association of Specific Microbial Taxa with Disease Severity in IBD Patients

Microbial Taxa	Correlation with Disease Severity (p-value)
Faecalibacterium prausnitzii	Negative ($p < 0.01$)
Adherent-invasive Escherichia coli (AIEC)	Positive ($p < 0.05$)

Correlation analyses revealed associations between gut microbiota composition and disease severity in IBD patients. Higher abundance of pathogenic bacteria such as AIEC was positively correlated with disease activity scores, as assessed by validated clinical indices (e.g., Ulcerative Colitis Disease Activity Index [UCDAI], Crohn's Disease Activity Index [CDAI]) ($p < 0.05$). On the other hand, fewer helpful microorganisms, such as as *Faecalibacterium prausnitzii* was associated with increased disease severity and poorer clinical outcomes ($p < 0.01$).

Dietary habits were found to influence gut microbiota composition in IBD patients. Specifically, consumption of a Western-style diet rich in processed foods, saturated fats, and sugars was associated with dysbiosis and increased inflammation in IBD patients ($p < 0.05$). In contrast, Following a Mediterranean-style diet that emphasizes eating plenty of fruits, vegetables, whole grains, and healthy fats was linked to lower disease activity and increased microbial diversity in IBD patients ($p < 0.01$).

Subgroup analyses based on disease subtype (Crohn's disease vs. ulcerative colitis) and treatment status (medication-naive vs. on treatment) revealed differential patterns of gut microbiota composition and associations with disease characteristics. For example, patients with Crohn's disease exhibited distinct alterations in microbial taxa compared to those with ulcerative colitis, reflecting differences in disease pathophysiology and mucosal involvement ($p < 0.05$).

Discussion

The results of this work add to the increasing corpus of knowledge on the function of the gut flora in IBD. Examining our findings in relation to prior research and studies offers vital insights into the coherence and replicability of outcomes across diverse populations and environments.

Our findings confirms prior research that shows changes in the makeup of gut microbiota in patients with IBD compared to healthy individuals [13, 14]. In line with previous research, we saw a decline in the variety of microorganisms and changes in the proportion of important groups, such as a rise in Proteobacteria and a drop in Firmicutes [15, 16]. These data emphasize that dysbiosis is a common characteristic of IBD in many groups of patients. It is crucial to acknowledge the differences in distinct microbial groups reported in various investigations [17]. For instance, whereas our research observed a decrease in the prevalence of *Faecalibacterium prausnitzii*, other investigations have reported contradictory findings. For example, a research discovered that there were no notable variations in the amount of *Faecalibacterium prausnitzii* between people with IBD and those without the condition [18, 19].

This suggests that there may be variances in the microbial compositions across different populations. There have been reports in the literature on differences in the prevalence of disease-causing species such adherent-invasive Escherichia coli (AIEC) [20, 21]. While our research demonstrated a higher prevalence of AIEC in individuals with IBD, other investigations have reported contradictory findings or identified relationships with other pathogenic microorganisms [22]. The variations seen might be attributed to disparities in the methodology of the research, the procedures used to handle the samples, and the characteristics of the patients. This emphasizes the intricate nature of microbial dysbiosis in IBD. Our work offers more proof of the connections between the makeup of gut microbiota and the severity of diseases in people with IBD [23, 24]. In line with other studies, our findings indicate that an increased presence of harmful bacteria, such as AIEC, is directly linked to higher disease activity scores. Conversely, a decreased presence of helpful bacteria, including *Faecalibacterium prausnitzii*, is associated with more severe illness [25]. These results indicate possible biomarkers that might be used to predict the course of illness and the effectiveness of treatment in individuals with IBD. This study builds upon prior research by examining the influence of dietary variables on the makeup of gut microbiota and the consequences of illness in individuals with IBD. Previous research have shown that following a Mediterranean-style diet is linked to positive microbial profiles and decreased disease activity. Our results further support the idea that dietary treatments might be effective in managing IBD.

Study Limitations and Future Directions

A number of limitations must be noted. Firstly, the longitudinal evaluation of microbial dynamics over time and causal inference are not possible due to the cross-sectional methodology. To clarify the temporal links between gut microbiota dysbiosis and IBD disease development, longitudinal research approaches will be required in future investigations. The research was limited to a single site, which might have an impact on how broadly the results can be applied. We recommend multi-center investigations with a range of patient populations to corroborate our results and detect any regional or ethnic variations in the makeup of the gut microbiota and its relationships to inflammatory bowel disease.

Conclusion

The research offers proof of dysbiotic gut microbiota in IBD and links it to dietary variables and the severity of the illness. The findings underscore the therapeutic promise of targeting the gut microbiota for restoring inflammation & microbial balance in individuals with IBD. In order to optimize treatment approaches and enhance patient outcomes, more research is required to

clarify the intricate interactions among gut microbiota, host characteristics, and environmental variables that shape disease susceptibility and outcomes in IBD.

Conflict of interest

The authors state no conflict of interest.

Author Contributions

All authors contributed equally in this study, provided agreement to be accountable for all aspects of the work and give final approval of the version to be published.

References

1. Santana PT, Rosas SL, Ribeiro BE, Marinho Y, de Souza HS. Dysbiosis in inflammatory bowel disease: pathogenic role and potential therapeutic targets. International journal of molecular sciences. 2022 Mar 23;23(7):3464.
2. Lane ER, Zisman TL, Suskind DL. The microbiota in inflammatory bowel disease: current and therapeutic insights. Journal of inflammation research. 2017 Jun 10:63-73.
3. Zuo T, Ng SC. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Frontiers in microbiology. 2018 Sep 25;9:365492.
4. Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The gut microbiota in inflammatory bowel disease. Frontiers in cellular and infection microbiology. 2022 Feb 22;12:733992.
5. Yuan S, Wang KS, Meng H, Hou XT, Xue JC, Liu BH, Cheng WW, Li J, Zhang HM, Nan JX, Zhang QG. The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:114893.
6. Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R, Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosnian Journal of Basic Medical Sciences. 2021 Jun;21(3):270.
7. Mukherjee S, Joardar N, Sengupta S, Babu SP. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: lessons from recent findings. The Journal of nutritional biochemistry. 2018 Nov 1;61:111-28.
8. Katsanos KH, Papadakis KA. Inflammatory bowel disease: updates on molecular targets for biologics. Gut and Liver. 2017 Jul;11(4):455.
9. Amoroso C, Perillo F, Strati F, Fantini M, Caprioli F, Facciotti F. The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation. Cells. 2020 May 16;9(5):1234.
10. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of gut microbiota in IBD: cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019 Aug 13;8(3):126.
11. Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M. Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. World journal of gastrointestinal oncology. 2022 Mar 3;14(3):547.
12. Yue B, Yu ZL, Lv C, Geng XL, Wang ZT, Dou W. Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease. World Journal of Gastroenterology. 2020 Aug 8;26(30):4378.
13. Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. InMayo Clinic Proceedings 2019 Jan 1 (Vol. 94, No. 1, pp. 155-165). Elsevier.
14. Michalak A, Mosińska P, Fichna J. Common links between metabolic syndrome and inflammatory bowel disease: current overview and future perspectives. Pharmacological Reports. 2016 Aug 1;68(4):837-46.
15. Ahlawat S, Kumar P, Mohan H, Goyal S, Sharma KK. Inflammatory bowel disease: tri-directional relationship between microbiota, immune system and intestinal epithelium. Critical Reviews in Microbiology. 2021 Mar 4;47(2):254-73.
16. Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Frontiers in medicine. 2021 Dec 20;8:765474.
17. Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune network. 2017 Feb;17(1):25.
18. Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging therapies for inflammatory bowel disease. Advances in therapy. 2018 Nov;35:1746-62.
19. Wang M, Shi J, Yu C, Zhang X, Xu G, Xu Z, Ma Y. Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds?. Frontiers in Immunology. 2023 Dec 14;14:1298186.
20. Castro-Dopico T, Colombel JF, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Current opinion in pharmacology. 2020 Dec 1;55:90-8.
21. .
22. Sakhaee K, Poindexter J, Aguirre C. The effects of bariatric surgery on bone and nephrolithiasis. Bone. 2016 Mar 1;84:1-8.
23. Ding Q, Ouyang J, Fan B, Cao C, Fan Z, Ding L, Li F, Tu W, Jin X, Wang J, Shi Y. Association between dyslipidemia and nephrolithiasis risk in a Chinese population. Urologia internationalis. 2019 Jan 23;103(2):156-65.
24. Chang CW, Ke HL, Lee JI, Lee YC, Jhan JH, Wang HS, Shen JT, Tsao YH, Huang SP, Geng JH. Metabolic syndrome increases the risk of kidney stone disease: a

cross-sectional and longitudinal cohort study. Journal of personalized medicine. 2021 Nov 6;11(11):1154.

25. Khan J, Shaw S. Risk of multiple lower and upper urinary tract problems among male older adults with type-2 diabetes: a population-based study. The Aging Male. 2023 Dec 31;26(1):2208658.